0VGI.L
TG Therapeutics, Inc. is a biopharmaceutical firm already generating revenue, dedicated to discovering, advancing, and bringing to market innovative therapies for a range of B-cell cancers and autoimmune conditions. Among its pipeline of therapeutic agents are Ublituximab, an experimental glycoengineered monoclonal antibody targeting B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and various forms of relapsing multiple sclerosis. Also featured is Umbralisib, an orally administered inhibitor specifically designed for PI3K-delta and CK1-epsilon, which addresses CLL, marginal zone lymphoma, and follicular lymphoma. The company's portfolio further includes Cosibelimab, a human ...[Read more]
Industry
Medical - Pharmaceuticals
IPO Date
2018-11-23
Stock Exchange
LSE
Ticker
0VGI.L
According to TG Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 20.69. This represents a change of -76.97% compared to the average of 89.86 of the last 4 quarters.
The mean historical PE Ratio of TG Therapeutics, Inc. over the last ten years is 33.75. The current 20.69 PE Ratio has changed 6.03% with respect to the historical average. Over the past ten years (40 quarters), 0VGI.L's PE Ratio was at its highest in in the March 2025 quarter at 285.72. The PE Ratio was at its lowest in in the March 2024 quarter at -50.44.
Average
33.75
Median
-3.60
Minimum
-21.50
Maximum
191.27
Discovering the peaks and valleys of TG Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 279.57%
Maximum Annual PE Ratio = 191.27
Minimum Annual Increase = -2460.50%
Minimum Annual PE Ratio = -21.50
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | 9.62 | -94.89% |
| 2024 | 188.13 | -1.64% |
| 2023 | 191.27 | -2460.50% |
| 2022 | -8.10 | 12.16% |
| 2021 | -7.22 | -66.39% |
| 2020 | -21.50 | 279.57% |
| 2019 | -5.66 | 217.70% |
| 2018 | -1.78 | -58.48% |
| 2017 | -4.29 | 47.72% |
| 2016 | -2.91 | -66.38% |
The current PE Ratio of TG Therapeutics, Inc. (0VGI.L) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
129.67
5-year avg
74.74
10-year avg
33.75
TG Therapeutics, Inc.’s PE Ratio is greater than Axsome Therapeutics, Inc. (-43.26), greater than Arrowhead Pharmaceuticals, Inc. (-26.06), greater than Viking Therapeutics, Inc. (-5.47), greater than Amicus Therapeutics, Inc. (-783.24), less than Halozyme Therapeutics, Inc. (33.19), greater than Perrigo Company plc (-1.28), greater than Agios Pharmaceuticals, Inc. (-4.42), greater than Sarepta Therapeutics, Inc. (-11.69), greater than Supernus Pharmaceuticals, Inc. (-20.91), less than Corcept Therapeutics Incorporated (223.52),
| Company | PE Ratio | Market cap |
|---|---|---|
| -43.26 | N/A | |
| -26.06 | N/A | |
| -5.47 | N/A | |
| -783.24 | N/A | |
| 33.19 | N/A | |
| -1.28 | N/A | |
| -4.42 | N/A | |
| -11.69 | N/A | |
| -20.91 | N/A | |
| 223.52 | N/A |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like TG Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like TG Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is TG Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for TG Therapeutics, Inc. (0VGI.L)?
What is the highest PE Ratio for TG Therapeutics, Inc. (0VGI.L)?
What is the 3-year average PE Ratio for TG Therapeutics, Inc. (0VGI.L)?
What is the 5-year average PE Ratio for TG Therapeutics, Inc. (0VGI.L)?
How does the current PE Ratio for TG Therapeutics, Inc. (0VGI.L) compare to its historical average?